No Data
Mizuho Adjusts PT on BioXcel Therapeutics to $1 From $4 on Solvency Concerns, Uncertainty; Keeps Neutral Rating
Bioxcel Therapeutics (BTAI) Receives a Hold From Mizuho Securities
Express News | BioXcel Therapeutics Inc : Mizuho Cuts Target Price to $1 From $4
Earnings Call Summary | BioXcel Therapeutics(BTAI.US) Q2 2024 Earnings Conference
BioXcel Therapeutics, Inc. (BTAI) Q2 2024 Earnings Call Transcript
BioXcel Therapeutics Is Maintained at Neutral by UBS